IN2015DN01328A - - Google Patents

Info

Publication number
IN2015DN01328A
IN2015DN01328A IN1328DEN2015A IN2015DN01328A IN 2015DN01328 A IN2015DN01328 A IN 2015DN01328A IN 1328DEN2015 A IN1328DEN2015 A IN 1328DEN2015A IN 2015DN01328 A IN2015DN01328 A IN 2015DN01328A
Authority
IN
India
Prior art keywords
compounds
present
therapeutic
cancer
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Michael Patrick Dillon
Mika Lindvall
Daniel Poon
Savithri Ramurthy
Vivek Rauniyar
Cynthia Shafer
Sharadha Subramanian
Huw Tanner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2015DN01328A publication Critical patent/IN2015DN01328A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1328DEN2015 2012-09-19 2013-09-17 IN2015DN01328A (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702981P 2012-09-19 2012-09-19
PCT/US2013/060032 WO2014047020A1 (en) 2012-09-19 2013-09-17 Dihydropyrrolidino-pyrimidines as kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2015DN01328A true IN2015DN01328A (el) 2015-07-03

Family

ID=49274870

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1328DEN2015 IN2015DN01328A (el) 2012-09-19 2013-09-17

Country Status (13)

Country Link
US (1) US9546173B2 (el)
EP (1) EP2897961B1 (el)
JP (1) JP6186440B2 (el)
KR (1) KR20150056550A (el)
CN (1) CN104640865B (el)
AU (1) AU2013318283A1 (el)
BR (1) BR112015005982A2 (el)
CA (1) CA2882410A1 (el)
EA (1) EA201590600A1 (el)
ES (1) ES2612885T3 (el)
IN (1) IN2015DN01328A (el)
MX (1) MX2015003535A (el)
WO (1) WO2014047020A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015003535A (es) * 2012-09-19 2015-07-14 Novartis Ag Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa.
CA3103711A1 (en) * 2018-07-12 2020-01-16 UCB Biopharma SRL Spirocyclic indane analogues as il-17 modulators
WO2020243457A1 (en) * 2019-05-29 2020-12-03 Viogen Biosciences, Llc Compounds and therapeutic uses thereof
KR20220042184A (ko) * 2019-08-01 2022-04-04 프레테고 인코포레이티드 최종 당화 산물의 억제제
IL292349A (en) * 2019-12-10 2022-06-01 Hoffmann La Roche Novel braf inhibitors as paradox breakers
CR20220251A (es) 2019-12-10 2022-07-11 Hoffmann La Roche Nuevos derivados de metilquinazolinona
WO2021218912A1 (zh) * 2020-04-30 2021-11-04 南京明德新药研发有限公司 含苯基并内磺酰胺的化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4530852B2 (ja) * 2002-07-15 2010-08-25 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病治療のためのピペリジノピリミジンジペプチジルペプチダーゼ阻害剤
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2005068468A2 (en) * 2003-12-02 2005-07-28 Vertex Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors and uses thereof
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
SI1838718T1 (sl) 2005-01-10 2011-08-31 Pfizer Pirolopirazoli, zmogljivi inhibitorji kinaze
DK1966151T3 (da) 2005-12-13 2012-01-30 Schering Corp Polycykliske indazolderivater, der er ERK-hæmmere
NZ581698A (en) 2007-06-05 2012-09-28 Merck Sharp & Dohme Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) * 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
CN103298461A (zh) 2010-11-17 2013-09-11 霍夫曼-拉罗奇有限公司 治疗肿瘤的方法
BR112013021896A2 (pt) 2011-02-28 2016-11-08 Array Biopharma Inc inibidores de serina/treonina cinase
ES2620612T3 (es) * 2012-03-02 2017-06-29 Genentech, Inc. Derivados de sulfóxidos y sulfonas de piridinilo y pirimidinilo
MX2015003535A (es) * 2012-09-19 2015-07-14 Novartis Ag Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa.

Also Published As

Publication number Publication date
EA201590600A1 (ru) 2015-07-30
ES2612885T3 (es) 2017-05-19
US9546173B2 (en) 2017-01-17
MX2015003535A (es) 2015-07-14
AU2013318283A1 (en) 2015-03-05
EP2897961A1 (en) 2015-07-29
CA2882410A1 (en) 2014-03-27
BR112015005982A2 (pt) 2017-07-04
WO2014047020A1 (en) 2014-03-27
CN104640865A (zh) 2015-05-20
JP2015529248A (ja) 2015-10-05
KR20150056550A (ko) 2015-05-26
US20150274733A1 (en) 2015-10-01
JP6186440B2 (ja) 2017-08-23
EP2897961B1 (en) 2016-10-26
CN104640865B (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
JO3366B1 (ar) مثبطات بيرازوليل كوينوكزالين كاينيز
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
EP3603661A3 (en) Rna containing composition for treatment of tumor diseases
IN2015DN01328A (el)
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
PH12015501385A1 (en) Autotaxin inhibitors
GT201500051A (es) Inhibidores de glucosilceramida sintasa
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
UA111386C2 (uk) Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ
IN2014MN00986A (el)
GB201209613D0 (en) New compounds
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
JO3438B1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
MX343706B (es) Derivados heterocíclicos novedosos.
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
GEP201606566B (en) Isoxazolidine derivatives
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
MX2017003016A (es) Derivados de piridazinona como inhibidores de las fosfoinositido-3-cinasas.
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина